Your browser doesn't support javascript.
loading
Factors associated with the use of psychedelics, ketamine and MDMA among sexual and gender minority youths in Canada: a machine learning analysis.
Dharma, Christoffer; Liu, Esther; Grace, Daniel; Logie, Carmen; Abramovich, Alex; Mitsakakis, Nicholas; Baskerville, Bruce; Chaiton, Michael.
Affiliation
  • Dharma C; University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada chris.dharma@mail.utoronto.ca.
  • Liu E; Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Grace D; Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Logie C; Department of Human Biology, University of Toronto, Toronto, Ontario, Canada.
  • Abramovich A; University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
  • Mitsakakis N; Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario, Canada.
  • Baskerville B; United Nations University Institute for Water Environment and Health, Hamilton, Ontario, Canada.
  • Chaiton M; University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
J Epidemiol Community Health ; 78(4): 248-254, 2024 03 08.
Article de En | MEDLINE | ID: mdl-38262735
ABSTRACT

BACKGROUND:

Substance use is increasing among sexual and gender minority youth (SGMY). This increase may be due to changes in social norms and socialisation, or due to SGMY exploring the potential therapeutic value of drugs such as psychedelics. We identified predictors of psychedelics, MDMA and ketamine use.

METHODS:

Data were obtained from 1414 SGMY participants who completed the ongoing longitudinal 2SLGBTQ+ Tobacco Project in Canada between November 2020 to January 2021. We examined the association between 80 potential features (including sociodemographic factors, mental health-related factors and substance use-related factors) with the use of psychedelics, MDMA and ketamine in the past year. Random forest classifier was used to identify the predictors most associated with reported use of these drugs.

RESULTS:

18.1% of participants have used psychedelics in the past year; 21.9% used at least one of the three drugs. Cannabis and cocaine use were the predictors most strongly associated with any of these drugs, while cannabis, but not cocaine use, was the one most associated with psychedelic use. Other mental health and 2SLGBTQ+ stigma-related factors were also associated with the use of these drugs.

CONCLUSION:

The use of psychedelics, MDMA and ketamine among 2SLGBTQ+ individuals appeared to be largely driven by those who used them together with other drugs. Depression scores also appeared in the top 10 factors associated with these illicit drugs, suggesting that there were individuals who may benefit from the potential therapeutic value of these drugs. These characteristics should be further investigated in future studies.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: N-Méthyl-3,4-méthylènedioxy-amphétamine / Troubles liés à une substance / Hallucinogènes / Kétamine Type d'étude: Prognostic_studies / Risk_factors_studies Aspects: Determinantes_sociais_saude Limites: Adolescent / Humans Pays/Région comme sujet: America do norte Langue: En Journal: J Epidemiol Community Health / J. epidemiol. community health (1979) / Journal of epidemiology and community health (1979) Année: 2024 Type de document: Article Pays d'affiliation: Canada Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: N-Méthyl-3,4-méthylènedioxy-amphétamine / Troubles liés à une substance / Hallucinogènes / Kétamine Type d'étude: Prognostic_studies / Risk_factors_studies Aspects: Determinantes_sociais_saude Limites: Adolescent / Humans Pays/Région comme sujet: America do norte Langue: En Journal: J Epidemiol Community Health / J. epidemiol. community health (1979) / Journal of epidemiology and community health (1979) Année: 2024 Type de document: Article Pays d'affiliation: Canada Pays de publication: Royaume-Uni